ampe_Ex10_1


		
			Exhibit 10.1
		

		
			WARRANT EXERCISE AGREEMENT
		

		
			This Warrant Exercise Agreement (this “Agreement”), dated as of October 28, 2019, is by and between Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned holder (the “Holder”) of a Common Stock Purchase Warrant to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), issued by the Company, which warrant is exercisable at an exercise price (the “Exercise Price”) per share as set forth on the Holder’s signature page hereto (the “Original Warrant”).
		

		
			WHEREAS, the Holder’s Original Warrant is exercisable into a number of shares of Common Stock as set forth on the Holder’s signature page hereto (the “Warrant Shares”);
		

		
			WHEREAS, the Holder wishes to exercise all or a portion of such Original Warrant as set forth herein and, immediately prior to such exercise and in consideration of the Holder’s exercise of such Original Warrant, the Company has agreed to issue the Holder the shares of Common Stock to which such exercising Holder is entitled.
		

		
			NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Holder and the Company agree as follows:
		

		
			ARTICLE I
		

		
			DEFINITIONS
		

		
			Section 1.1      Definitions. Capitalized terms not defined in this Agreement shall have the meanings ascribed to such terms in the Original Warrant.
		

		
			ARTICLE II
		

		
			EXERCISE OF EXISTING WARRANT
		

		
			Section 2.1      Exercise of Original Warrant. The Company and the Holder hereby agree that the Holder shall immediately exercise the Original Warrant with respect to the number of Warrant Shares set forth on the Holder’s signature page hereto at a reduced Exercise Price per share equal to $0.215, otherwise pursuant to the terms of the Original Warrant, representing a discount from the Exercise Price of the Original Warrant as indicated on the Holder Signature Page to this Agreement (in the aggregate, collectively, the “Early Exercise  Discount”). The Holder shall deliver the aggregate cash exercise price for such exercise of the Original Warrant, giving effect to the Early Exercise Discount, to the bank account set forth on Annex A hereto within one business day following the date of this Agreement and the Company shall deliver the Warrant Shares to the Holder via the Depository Trust Company Deposit or Withdrawal at Custodian (“DWAC”) system pursuant to the terms of the Original Warrant, except that the Company shall deliver the applicable Warrant Shares to the Holder no later than the later of (x) two (2) Trading Days following the date of this Agreement and (y) one (1) Trading Day following delivery of the aggregate cash exercise price, giving effect to the Early Exercise Discount, and pursuant to DWAC instructions set forth on the Holder’s signature page hereto.  The date of the closing of the exercise of the Original Warrant shall be referred to as the “Closing Date”.
		

		
			
		

		
			


		 





		

		
			 
		

		
			Section 2.2      Filing of Form 8-K. Prior to 9:00 am ET on the Trading Day following the date hereof, the Company shall issue a Current Report on Form 8-K, reasonably acceptable to the Holder disclosing the material terms of the transactions contemplated hereby, which shall include this Agreement (the “8-K Filing”). From and after the 8-K Filing, the Holder shall not be in possession of any material, nonpublic information received from the Company, any of its subsidiaries or any of their respective officers, directors, employees or agents that is not disclosed in the 8-K Filing. In addition, effective upon the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Holder or any of its affiliates, on the other hand, shall terminate.
		

		
			ARTICLE III
		

		
			REPRESENTATIONS AND WARRANTIES
		

		
			Section 3.1     Representations and Warranties of the Company. The Company hereby makes the representations and warranties set forth below to the Holder that as of the date of its execution of this Agreement:
		

		
			(a)        Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part of such Company and no further action is required by such Company, its board of directors or its stockholders in connection therewith. This Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.
		

		
			(b)        Organization. The Company is a duly organized and validly existing corporation in good standing under the laws of the State of Delaware.
		

		
			(c)        Registration Statement. The Warrant Shares are registered for issuance to the Holder on the registration statement on Form S-3 (No. 333-217094) (the “Registration Statement”), and the Company knows of no reasons why such Registration Statement shall not remain available for the issuance of such Warrant Shares for the foreseeable future. At the time the Registration Statement and any amendments thereto became effective and as of the date hereof the Registration Statement and any amendments thereto complied and will comply in all material respects with the requirements of the Securities Act of 1933, as amended (the “Securities Act”) and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to
		

		
			
		

		
			


		 





		

		
			 
		

		
			make the statements therein not misleading. The Prospectus contained in the Registration Statement (the “Prospectus”) and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and as of the date hereof, complied, and will comply, in all material respects with the requirements of the Securities Act and did not, and will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.  The Registration Statement is effective and available for the issuance of the Warrant Shares and the Company has not received any notice that the Securities and Exchange Commission (the “SEC”) has issued or intends to issue a stop-order with respect to the Registration Statement or that the SEC otherwise has suspended or withdrawn the effectiveness of the Registration Statement, either temporarily or permanently, or intends or has threatened in writing to do so.  The Registration Statement and any prospectus included therein, complied in all material respects with the requirements of the 1933 Act and the Securities Exchange Act of 1934, as amended, and the rules and regulations of the SEC promulgated thereunder and all other applicable laws and regulations.  The Company shall use commercially reasonable efforts to keep the Registration Statement effective and available for use by the Holder until all Warrant Shares are issued to the Holder.  The Warrant Shares shall be issued without restrictive legend and shall be immediately freely-tradable by Holder.
		

		
			(d)        No Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien upon any of the properties or assets of the Company, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which the Company is a party or by which any property or asset of the Company is bound or affected, or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected.
		

		
			(e)        Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by this Agreement, the Company confirms that neither it nor any other Person acting on its behalf has provided the Holder or any of its agents or counsel with any information that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the Holder will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosures furnished by or on behalf of the Company to the Holder regarding the Company and its subsidiaries, their respective businesses and the transactions contemplated hereby, including but not limited to the disclosure set forth in the SEC Reports, are true and correct and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under
		

		
			
		

		
			


		 





		

		
			 
		

		
			which they were made, not misleading. As used herein, “SEC Reports” means all reports, schedules, forms, statements and other documents required to be filed by the Company with the Commission pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended, including all exhibits included therein and financial statements, notes and schedules thereto and documents incorporated by reference therein.
		

		
			(f)        No Disqualification Events. With respect to securities to be offered and sold hereunder in reliance on Rule 506(b) under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company, any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person” and, together, “Issuer Covered Persons”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Holder a copy of any disclosures provided thereunder, if any.
		

		
			(g)        Brokers. Except for ThinkEquity, a division of Fordham Financial Management, Inc., no broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement.
		

		
			Section 3.2      Representations and Warranties of the Holder. The Holder hereby makes the representations and warranties set forth below to the Company that as of the date of its execution of this Agreement:
		

		
			(a)        Due Authorization. The Holder represents and warrants that (i) the execution and delivery of this Agreement by it and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on its behalf and (ii) this Agreement has been duly executed and delivered by the Holder and constitutes the valid and binding obligation of the Holder, enforceable against it in accordance with its terms.
		

		
			(b)        No Conflicts. The execution, delivery and performance of this Agreement by the Holder and the consummation by the Holder of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Holder’s organizational or charter documents, or (ii) conflict with or result in a violation of any agreement, law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority which would interfere with the ability of the Holder to perform its obligations under this Agreement.
		

		
			(c)        Access to Information.  The Holder acknowledges that it has had the opportunity to review this Agreement and the SEC Reports and has been afforded (i) the
		

		
			
		

		
			


		 





		

		
			 
		

		
			opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the exercise of the Original Warrant and the merits and risks of investing in the Warrant Shares underlying the Original Warrant; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. The Holder acknowledges and agrees that neither the Company, Canaccord Genuity LLC, ThinkEquity, a division of Fordham Financial Management, Inc. (collectively, the “Agents”) nor any Affiliate of the Agents has provided the Holder with any information or advice with respect to the Original Warrant, the Warrant Shares or the securities nor is such information or advice necessary or desired. Neither the Agents nor any Affiliate of the Agents has made or makes any representation as to the Company or the quality of the Original Warrant, the Warrant Shares or the securities, and the Agents and any Affiliate of the Agents may have acquired non-public information with respect to the Company which the Holder agrees need not be provided to it. In connection with the issuance of the Warrant Shares and the Securities to the Holder, neither the Agents nor any of their respective Affiliates has acted as a financial advisor or fiduciary to the Holder.
		

		
			(d)        Holder Status. The Holder is an “accredited investor” as defined in Rule 501 under the Securities Act.
		

		
			ARTICLE IV
		

		
			MISCELLANEOUS
		

		
			Section 4.1      Standstill. From the date hereof until thirty (30) Trading Days after the date hereof, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock equivalents or (ii) file any registration statement or amendment or supplement to any registration statement. The prohibition in clause (i) above shall not apply to the Company’s issuance of securities upon the exercise or exchange of or conversion of any securities exercisable or exchangeable for or convertible into shares of Common Stock, or other similar rights, issued and outstanding on the date of this Agreement, provided that such outstanding securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than any amendment pursuant to any other substantially identical agreement related to the exercise of warrants). The prohibition in clause (ii) above shall not be interpreted as a prohibition on the filing those documents that may be incorporated by reference into any currently filed registration statement or the filing of a Form S-8.  “Trading Days” means a day on which the New York Stock Exchange is open for trading.
		

		
			Section 4.2      No Cashless Exercise.  Holder acknowledges and agrees that it is not entitled to exercise the Original Warrant by means of Cashless Exercise (as defined in the Original Warrant).
		

		
			
		

		
			


		 





		

		
			 
		

		
			Section 4.3      Most Favored Nation.  Company hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof that none of the terms offered to any other holder of the same class as the Original Warrant relating to the amendment or early exercise thereof (the “Future Warrant Agreement”) is or will be more favorable to such person than those of the Holder and this Agreement shall be, without any further action by Holder or Company, deemed amended and modified in an economically and legally equivalent manner such that Holder shall receive the benefit of the more favorable terms contained in such Future Warrant Agreement.
		

		
			Section 4.4      Future Fundamental Transaction.  In the event that a Fundamental Transaction (as defined in the Original Warrant) is announced or completed within six (6) months of the date hereof, notwithstanding the early exercise contemplated hereby, Section 4(c) of the Original Warrant shall be applicable as if Holder had not exercised the Original Warrant or sold any of the Warrant Shares and Holder shall be entitled to receive from the Company the difference, if greater, between (a) the aggregate Black Scholes Value of the Original Warrant, less (b) the aggregate Early Exercise Discount.
		

		
			Section 4.5      Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be made by email to the email address of the Holder set forth on the Holder’s signature page.
		

		
			Section 4.6     Survival. All warranties and representations (as of the date such warranties and representations were made) made herein or in any certificate or other instrument delivered by any party hereto or on its behalf under this Agreement shall be considered to have been relied upon by the parties hereto and shall survive the issuance of the Warrant Shares. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties; provided,  however that no party may assign this Agreement or the obligations and rights of such party hereunder without the prior written consent of the other parties hereto.
		

		
			Section 4.7      Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile or electronic transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or electronic signature page were an original thereof.
		

		
			Section 4.8      Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement.
		

		
			Section 4.9      Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined pursuant to the Governing Law provision of the Original Warrant.
		

		
			
		

		
			


		 





		

		
			 
		

		
			Section 4.10    Entire Agreement. The Agreement, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.
		

		
			Section 4.11    Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.
		

		
			Section 4.12    Fees and Expenses. Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Warrant Shares.
		

		
			[Remainder of page intentionally left blank.]
		

		
			 
		

		
			
		

		
			


		 





		

		
			 
		

		
			IN WITNESS WHEREOF, the undersigned have executed this Warrant Exercise Agreement as of the date first written above.
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						COMPANY:

				
	
					
						AMPIO PHARMACEUTICALS, INC.

				
	
					
						 

					
					
						 

				
	
					
						By:

					
					
						 

					
					
						 

				
	
					
						Name:

					
					
						Daniel Stokely

				
	
					
						Title:

					
					
						Chief Financial Officer

				



		
			 
		

		
			Bank Account and Wire Instructions attached hereto on Annex A
		

		
			 
		

		
			
		

		
			


		 





		

		
			HOLDER SIGNATURE PAGE TO
		

		
			WARRANT EXERCISE AGREEMENT
		

		
			 
		

		
			IN WITNESS WHEREOF, the undersigned have caused this Warrant Exercise Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
		

		
			 
		

			
					
						Name of Holder:

					
					
						 

				



		
			 
		

			
					
						Signature of Authorized Signatory of Holder:

					
					
						 

				



		
			 
		

			
					
						Name of Authorized Signatory:

					
					
						 

				



		
			 
		

			
					
						Title of Authorized Signatory:

					
					
						 

				



		
			 
		

			
					
						Email Address of Holder:

					
					
						 

				



		
			 
		

			
					
						Number of Shares Exercisable under Original Warrant:

					
					
						 

				



		
			 
		

			
					
						Per Share Exercise Price under Original Warrant: 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						Per Share Early Exercise Discount:

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						Number of Warrant Shares Exercised Hereunder:

					
					
						 

				



		
			 
		

			
					
						Aggregate Exercise Price at $_0.215___ per Share: 

					
					
						 

				



		
			 
		

			
					
						DWAC Instructions for Warrant Shares:

					
					
						 

				



		
			 
		

		
			
		

		
			


		 





		

		
			 
		

		
			ANNEX A
		

		
			 
		

		
			
		

		
			Wiring Instructions to Ampio Pharmaceuticals, Inc.